Skip to Content

Astellas Pharma Inc ALPMF

Morningstar Rating
$10.55 +0.25 (2.43%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALPMF is trading at a 661% premium.
Price
$10.53
Fair Value
$49.52
Uncertainty
High
1-Star Price
$29.45
5-Star Price
$58.48
Economic Moat
Bmf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALPMF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$10.30
Day Range
$10.5510.55
52-Week Range
$9.1315.80
Bid/Ask
$9.90 / $11.35
Market Cap
$18.92 Bil
Volume/Avg
2,975 / 8,278

Key Statistics

Price/Earnings (Normalized)
23.60
Price/Sales
1.71
Dividend Yield (Trailing)
4.35%
Dividend Yield (Forward)
4.47%
Total Yield
4.74%

Company Profile

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
14,754

Comparables

Valuation

Metric
ALPMF
ENTA
RIGL
Price/Earnings (Normalized)
23.60
Price/Book Value
1.791.91
Price/Sales
1.714.341.53
Price/Cash Flow
10.59
Price/Earnings
ALPMF
ENTA
RIGL

Financial Strength

Metric
ALPMF
ENTA
RIGL
Quick Ratio
0.716.231.05
Current Ratio
0.936.431.26
Interest Coverage
2.13−12.14−1.95
Quick Ratio
ALPMF
ENTA
RIGL

Profitability

Metric
ALPMF
ENTA
RIGL
Return on Assets (Normalized)
2.04%−25.87%−7.25%
Return on Equity (Normalized)
4.11%−50.83%
Return on Invested Capital (Normalized)
2.94%−46.23%−11.44%
Return on Assets
ALPMF
ENTA
RIGL
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
DgzncljxKpjwn$790.8 Bil
Johnson & Johnson
JNJ
YtxyqtdfvTcks$366.7 Bil
Merck & Co Inc
MRK
MhlplpdrNgdv$315.0 Bil
AbbVie Inc
ABBV
GrqkngllrVnkhx$305.8 Bil
Roche Holding AG ADR
RHHBY
FgbzlqmsxJvhdl$247.7 Bil
AstraZeneca PLC ADR
AZN
KrkfcnryNypsl$244.4 Bil
Novartis AG ADR
NVS
ChshtklshKmkqx$218.8 Bil
Amgen Inc
AMGN
ZsgltxydvKcgny$178.8 Bil
Pfizer Inc
PFE
LzpvvsxjnLqvd$167.2 Bil
Sanofi SA ADR
SNY
HfnnmgrmRnz$126.4 Bil

Sponsor Center